23-valent pneumococcal polysaccharide vaccine

BIOLOGICAL17 trials

Sponsors

Genentech, Inc., Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer, Jiangsu Province Centers for Disease Control and Prevention, Biogen

Conditions

COVID-19InfluenzaPneumococcal Conjugate VaccinePneumococcal DiseasePneumococcal InfectionPneumococcal Infectious DiseasePneumococcal Vaccine Adverse ReactionPneumococcal Vaccines

Early Phase 1

Pneumonia Vaccine in Aging HIV Positive Individuals

CompletedNCT02558751

University of Toledo Health Science CampusPneumococcal Infection

Start: 2013-07-31End: 2015-06-30Updated: 2015-09-24

Phase 1

Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above

CompletedNCT05815264

Ab&B Bio-tech Co., Ltd.JSPneumonia

Start: 2020-09-07End: 2021-04-06Updated: 2026-01-02

Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine

CompletedNCT06703203

Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdPneumococcal Vaccines

Start: 2025-07-17End: 2026-02-05Updated: 2026-03-30

Phase 2

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

CompletedNCT00282308

Genentech, Inc.Rheumatoid Arthritis

Start: 2006-01-23End: 2012-05-28Updated: 2017-08-10

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

CompletedNCT02097849

BiogenRelapsing Forms of Multiple Sclerosis

Start: 2015-02-28End: 2016-05-02Updated: 2017-06-02

Phase 3

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

CompletedNCT00574548

Wyeth is now a wholly owned subsidiary of PfizerPneumococcal Vaccines

Start: 2007-11-30End: 2010-02-28Updated: 2011-07-22

A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

CompletedNCT01646398

PfizerPneumococcal Conjugate Vaccine, Pneumococcal Vaccines

Start: 2012-06-30End: 2012-10-31Updated: 2013-09-20

Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above

CompletedNCT04278248

Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdPneumonia, Pneumococcal

Start: 2018-01-12End: 2018-06-07Updated: 2020-02-20

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

RecruitingNCT06044077

Aimei Vacin BioPharm (Zhejiang) Co., Ltd.Pneumococcal Disease

Start: 2023-09-08End: 2029-07-31Target: 1920Updated: 2023-09-21

Phase 4

A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)

CompletedNCT01163747

Genentech, Inc.Rheumatoid Arthritis

Start: 2010-09-30End: 2012-06-30Updated: 2012-12-07

Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults

CompletedNCT02062281

Jiangsu Province Centers for Disease Control and PreventionInfluenza, Pneumococcal Infection

Start: 2013-11-30End: 2014-01-31Updated: 2014-02-13

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease

CompletedNCT03762824

Region SkaneRheumatoid Arthritis, Sjögren Syndrome, Spondyloarthritis +2

Start: 2016-06-14End: 2020-12-21Updated: 2023-03-29

A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old

CompletedNCT04700618

China National Biotec Group Company LimitedVaccination

Start: 2021-03-21End: 2022-02-13Updated: 2022-02-16

A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly

CompletedNCT04701788

China National Biotec Group Company LimitedVaccination

Start: 2021-03-30End: 2022-02-15Updated: 2022-02-16

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

CompletedNCT04953325

Sinovac Research and Development Co., Ltd.COVID-19

Start: 2021-07-09End: 2022-01-31Updated: 2022-04-14

Unknown Phase

Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.

Sungkyunkwan UniversityPneumococcal Vaccine Adverse Reaction

Start: 2021-08-01End: 2022-03-31Target: 1000000Updated: 2020-09-16

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

CompletedNCT07071701

Sinovac Biotech Co., LtdPneumococcal Infectious Disease

Start: 2022-07-02End: 2024-04-05Updated: 2025-07-17

Related Papers

Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2 Years and Older in China

Infectious Diseases and Therapy2026-02-23

Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China

Frontiers in Immunology2025-07-17

Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients.

2020-02-2214 citations

What’s happening in <i>Neurology</i> <sup>®</sup> <i>Neuroimmunology & Neuroinflammation</i>

Neurology2018-02-19

Immune response to vaccines is maintained in patients treated with dimethyl fumarate

Neurology Neuroimmunology & Neuroinflammation2017-11-1684 citations

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

2014-03-05114 citations

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)

Annals of the Rheumatic Diseases2014-01-22105 citations